Pinellia ternata-Coptidis Rhizoma herb pair suppresses Helicobacter pylori colonization via NLRP3-mediated pyroptosis
Yukun Lin1, Kunjing Liu1, Jiahui Chen2
1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Ethnopharmacological Relevance:
Pinellia ternata (Ban-xia) and Coptidis Rhizoma (Huang-lian) form a classic herb pair (BXHL) in traditional Chinese medicine that has demonstrated clinical efficacy against Helicobacter pylori (H. pylori) infection. However, its pharmacological mechanisms remain insufficiently defined.
Aim Of The Study:
This study aimed to (1) evaluate the anti-H. pylori colonization effects of BXHL in vitro and in vivo; (2) elucidate its mechanism through the NLRP3-mediated pyroptosis pathway; and (3) assess its influence on gastrointestinal microbiota and identify potential active components.
Materials And Methods:
BXHL composition was characterized by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Anti-H. pylori activity was examined using GES-1 cell co-culture and infected mouse models. Gene expression and signaling pathways were analyzed by RNA-seq, ELISA, RT-qPCR, Western blotting and IHC. Histopathology, bacterial load assays, and ultrastructural observation assessed anti-colonization efficacy. Microbiota alterations were analyzed via 16S rRNA sequencing and molecular docking evaluated interactions between BXHL compounds and NLRP3 targets.
Results:
BXHL significantly reduced H. pylori adhesion, colonization and restored NLRP3-mediated pyroptosis suppressed by infection. Transcriptomic and molecular analyses confirmed reactivation of the NLRP3 signaling cascade. BXHL preserved gut microbial diversity, unlike triple therapy, and exhibited moderate direct antibacterial effects.
Conclusion:
BXHL inhibits H. pylori colonization through suppressing bacterial adhesion factors and activating NLRP3-mediated pyroptosis, while causing no disruption to the gut microbiota. These findings position BXHL as a safe and effective adjunctive therapy, which provides a novel strategy to improve H. pylori eradication that complements conventional antibiotics.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...


